Table 1.
Baseline characteristics
| N (%) | ||
|---|---|---|
| Gender | Male | 17 (73.9) |
| Female | 6 (26.1) | |
| Mean age, years (SD) | 56.7 (8.5) | |
| Tumor grade | Glioblastoma | 13 (56.5) |
| Anaplastic glioma | 6 (26.1) | |
| Low-grade glioma | 4 (17.4) | |
| Primary caregiver | Partner | 22 (95.7) |
| Professional caregiver | 1 (4.3) | |
| Seizure type | Generalized | 12 (52.2) |
| Simple partial | 7 (30.4) | |
| Complex partial | 1 (4.3) | |
| Both partial and generalized | 3 (13.0) | |
| Seizure frequency before EOL phase | <1/month | 15 (65.2) |
| >1/month | 6 (26.1) | |
| >1/week | 2 (8.7) | |
| KPS at 1 week before death, mean (range) | 30 (20–50) | |
| Place of death | Home | 19 (82.6) |
| Hospice | 3 (13.0) | |
| Care hotel | 1 (4.3) | |
| Adherence to study protocol | Yes | 13 (56.5) |
| No | 6 (26.1) | |
| Use of oral AEDs until death | 4 (17.4) | |
| Use of buccal clonazepam (n = 19) | Yes | 13 (68.4) |
| No | 6 (31.6) | |
| Start date buccal clonazepam, days before death (n = 13) | >14 | 2 (15.4) |
| 7–14 | 2 (15.4) | |
| 3–7 | 2 (15.4) | |
| 1–3 | 5 (38.5) | |
| 1 | 2 (15.4) | |
| Use of intranasal midazolam (n = 19) | Yes | 6 (31.6) |
| No | 13 (68.4) | |